BioDelivery Sciences International Inc. (BDSI) recently announced that it has finished enrolling patients in a pivotal pharmacokinetic study (BNX 103) being conducted with BEMA buprenorphine/naloxone (BNX). The company also...
Read MoreSite: The market has wavered a bit in the last few trading sessions, but remains within striking distance of psychologically-important milestone levels. This begs the question: Can this rally be sustained going forward? My...
Read MoreHansen Medical (HNSN), a global developer and manufacturer of intravascular robotics, recently announced the expansion of its intellectual property portfolio on the back of 30 additional patents in the U.S. since January 2011....
Read MoreSpecialty and advanced materials company Rockwood Holdings Inc. (ROC) entered into an agreement to buy Talison Lithium Limited for C$724 million ($729 million) to boost the production of lithium used in batteries and...
Read MorePebblebrook Hotel Trust (PEB), a real estate investment trust (REIT), has recently acquired W Los Angeles – Westwood – a 258-room luxury full-service hotel in the Westwood neighborhood of Los Angeles, California, for...
Read MoreThe Global Engineering and Construction Group of Foster Wheeler AG (FWLT) received a contract from Petr?leo Brasileiro S.A. (Petrobras) (PBR) for the construction of a world-scale grassroots gas-to-chemicals complex in Linhares,...
Read MoreRoper Industries Inc. (ROP) recently completed the acquisition of privately-held Sunquest Information Systems Inc. for approximately $1.415 billion, including $25.0 million in cash tax benefits. Roper used its available cash and...
Read MoreDish Network Corp. (DISH) – the second largest satellite TV provider in the U.S. – again seems to get into trouble when the U.S. Federal Trade Commission (FTC) brought litigation against the company for infringing...
Read MoreWe are maintaining our Neutral recommendation on GOL Linhas A?reas Inteligentes S.A. (GOL) based on its long-term business strategy of route expansion and strategic acquisitions. However, uncertainty associated with declining...
Read MoreGlaxoSmithKline (GSK) and Janssen Biologics’ (Ireland) human anti-interleukin (IL)-6 monoclonal antibody, sirukumab (CNTO 136), recently moved into a phase III program. Sirukumab is being developed for the treatment of...
Read More
